Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Kiniksa Pharmaceuticals International, plc (KNSA) vs Liquidia Corporation (LQDA)

Kiniksa Pharmaceuticals International, plc and Liquidia Corporation are both Drug Manufacturers Specialty & Generic companies. Kiniksa Pharmaceuticals International, plc and Liquidia Corporation are of similar size ($6.4B and $5.9B). Liquidia Corporation trades at the lower P/E: 43.6× against 70.2×. Liquidia Corporation grew revenue faster over the last twelve months: 2,233.7% against 58.9%. Liquidia Corporation has the higher net margin (30.7% vs 9.59%) and the higher return on invested capital (121.1% vs 48.9%). Across the 20 metrics below, Liquidia Corporation leads on 11 and Kiniksa Pharmaceuticals International, plc on 9.

Valuation

Metric KNSA LQDA Drug Manufacturers Specialty & Generic median
P/E 70.17 43.59 20.14
P/S 6.93 13.49 2.25
P/B 8.90 31.17 1.90
Price to free cash flow 31.84 40.36 16.54
EV/EBITDA 51.93 35.09 12.29
EV/Sales 6.30 13.25 2.56
Earnings yield 1.43% 2.29% (2.99%)
Free cash flow yield 3.14% 2.48% 0.00%

Profitability

Metric KNSA LQDA Drug Manufacturers Specialty & Generic median
Gross margin 89.82% 92.54% 53.94%
Operating margin 11.92% 37.39% 0.00%
Net margin 9.59% 30.74% 0.00%
Free cash flow margin 21.74% 33.42% 0.00%
Return on equity 14.04% 131.82% (0.40%)
Return on assets 10.36% 35.57% (3.32%)
Return on invested capital 48.87% 121.05% 0.00%

Growth

Metric KNSA LQDA Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 58.85% 2,233.65% 10.01%
EPS growth (last fiscal year) 225.00% 51.81% —
Revenue growth, 5-year CAGR — 65.24% 6.74%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KNSA LQDA Drug Manufacturers Specialty & Generic median
Debt to equity 0.00 0.90 0.05
Current ratio 3.90 2.31 2.31
Net debt to EBITDA (5.26) (0.01) 0.85

Dividend

Metric KNSA LQDA Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric KNSA LQDA Drug Manufacturers Specialty & Generic median
Market cap 5.90b 6.36b 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack